BIBF 1120 (esylate)

BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRalpha, and PDGFRbeta, respectively). It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs, EC50s = 7-290 nM). In vivo, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFRbeta-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).Formal Name: (3Z)-2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid, methyl ester, monoethanesulfonate. CAS Number: 656247-18-6. Synonyms: Nintedanib. Molecular Formula: C31H33N5O4 . C2H6O3S. Formula Weight: 649.8. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 3 mg/ml, DMSO: 5 mg/ml, DMSO:PBS (pH 7.2) (1:5): 0.16 mg/ml. lambdamax: 287, 392 nm. SMILES: O=C1NC2=CC(C(OC)=O)=CC=C2/C1=C(C3=CC=CC=C3)/NC4=CC=C(N(C(CN5CCN(C)CC5)=O)C)C=C4.O=S(O)(CC)=O. InChi Code: InChI=1S/C31H33N5O4.C2H6O3S/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38,1-2-6(3,4)5/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38),2H2,1H3,(H,3,4,5)/b29-28-,. InChi Key: MMMVNAGRWOJNMW-FJBFXRHMSA-N.